Reference
Kass MA, Zimmerman T, Yablonski M, et al. Compliance to pilocarpine therapy [abstract no.2]. Invest Ophthalmol 1977; 108:2
Kass MA, Meltzer D, Gordon M. A miniature compliance monitor for ophthalmology. Arch Ophthalmol 1984; 102: 1550
Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7
Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199–204
Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5
Tashkin DP, Rand C, Nides M, et al. A nebulizer chronolog to monitor compliance with inhaler use. Am J Med 1991; 91 Suppl. 4A: 33S–6S
Mawhinney H, Spector SL, Kinsman RA, et al. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66: 294–9
Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298–305
Cheung R, Dickins J, Nicholson PW, et al. Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed recording device. Eur J Clin Pharmacol 1988; 35:401–7
Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 195–207
Urquhart J. Role of patient compliance in clinical pharmacokinetics: review of recent research. Clin Pharmacokinet 1994; 27:202–15
Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inf J 1988; 22: 363–78
Tritsmans L, Clincke G, Peelmans B. Does AAMI constitute a real disease entity? A placebo-controlled double-blind study with sabeluzole (R 58 735) in a patient population with real memory problems. Drug Dev Res 1990; 20: 473–82
Matsui D, Hermann C, Braudo M, et al. Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance. Clin Pharmacol Ther 1992; 52: 102–3
Matsuyama JR, Mason BJ, Jue SG. Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. Ann Pharmacother 1993; 27: 851–5
Steiner TJ, Catarci T, Hering R, et al. If migraine prophylaxis does not work, think about compliance. Cephalalgia 1994; 14: 463–4
Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 1995; 21: 52–7
Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 266–72
Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85
Kruse W, Eggert-Kruse W, Rampmaier J, et al. Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Clin Investig 1993; 71: 483–7
Mengden T, Binswanger B, Spühler T, et al. The use of selfmeasured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403–11
Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 453–7
Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7
de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug-therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol 1996; 35: 60–5
Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Comportement des patients ayant une hypertension arterielle legère a modrée vis-à-vis de leur traitement: apport du pilulier électronique. Ann Cardiol Angeiol 1995; 44: 597–605
Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49: 321–7
Girard P, Sheiner LB, Kastrissios H, Blaschke TF. A markov model for drug compliance, with application to HI V+ patients [abstract]. Clin Pharmacol Ther 1996; 59: 157
de Klerk E, van der Linden SJ, van der Heijden D, et al. Facilitated analysis of data on drug regimen compliance. Stat Med. In press
Rubin D. Comment: dose-response estimands. J Am Stat Assoc 1991; 86(413): 22–4
Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 301–22
Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991; 86(413): 9–17
Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 265–81
Sheiner LB, Rubin DB. Intention to treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995; 57: 6–15
Goetghebeur EJT, Pocock SJ. Statistical issues in allowing for noncompliance and withdrawal. Drug Inf J 1993; 27: 837–45
Mäenpää H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987; 8 Suppl. I: 39–43
Pullar T, Kumar S, Tindall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163–8
Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 1990; 245: 213–5
Temple R. Dose-response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA, editors. Dose-response relationships in clinical pharmacology. Amsterdam: Elsevier, 1989: 145–67
Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189–97
Guerrero D, Rudd P, Bryant-Kosling C, et al. Antihypertensive medication-taking: investigation of a simple regimen. Am J Hypertens 1993; 6: 586–92
Kruse W, Nikolaus T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993; 44: 211–5
Benet LZ, Øie S, Schwartz J. Design and optimization of dosage regimens: pharmacokinetic data. Appendix II. In: Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707–92
Benet LZ, Kroetz DL, Sheiner LB. Therapeutic drug monitoring. In Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:26
Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377–8
Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22: 238–46
Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care environment. In: Testa B, Meyer UA. Advances in drug research. London: Academic Press, 1995: 238–57
McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 Suppl. 1: S9–S195
NORPLANT System. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 2759–64
Grimes DA. Clinical crossroads: a 17-year old mother seeking contraception. JAMA 1996; 276: 1163–70
British National Formulary, no. 32. Sep 1996: 338
ORTHO-NOVUM Tablets. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 1872–80
Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1994; 1:260–7
Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, andpindolol. Am Heart J 1982; 104:473–8
Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116:515–23
Gilligan DM, Chan WL, Stewart R, et al. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 766–72
Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653–7
Feinstein AR, Spagnuolo M. Experimental reactivation of subsiding rheumatic fever. J Clin Invest 1961; 40: 1891–9
Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporinetreated renal transplants. Transplant Proc 1988; 20 Suppl. 3: 63–9
Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21(1): 833–4
De Geest S. Subclinical noncompliance with immunosuppressive therapy in heart transplant patients: a cluster analytic study [dissertation]. Leuven: Catholic University Leuven, 1995
Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol 1996; 88 Suppl.: 4S–12S
Petri H, Urquhart J. Patient compliance with beta-blocker medication in general practice. Pharmacoepidemiol Drug Saf 1994; 3: 251–6
Guillebaud J. Any questions. BMJ 1993; 307: 617
QUESTRAN (cholestyramine). Physicians’ desk reference. 50th ed. Oradell (NJ): Medical Economics, 1995: 770–1
The Lipid Research Clinic. The Lipid Research Clinic’s coronary primary prevention trial results: (I) reduction in incidence of coronary heart disease; (II) the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–74
Lasagna L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991:393–403
Vander Stichele RH, Thomson M, Verkoelen K, et al. Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in essential hypertension. Post-marketing Surveillance 1992; 6: 77–90
Petzinna D. Electronic compliance measurement and fraud. A A Drug Information Association Workshop on Drug Compliance Issues in Clinical Trials & Patient Care. 1996 Sept 30-Oct 1; Paris, 12
Kass MA, Meltzer D, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515–23
Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101:524–30
Kass MA, Gordon M, Morley RE, et al. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188–93
Geletko, SM, Segarra M, Mayer KH, et al. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrob Agents Chemother 1996; 40: 1338–41
Bakker A, Paes AHP, Soe-Agnie C. Improving compliance of oral antidiabetics through pharmacist’s intervention [abstract]: proceedings of the 23rd European symposium on clinical trials and pharmacoharmaco-epidemiology. Pharm World Sci 1994; Suppl. 6: G28
Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6
Norell SE. Methods in assessing drug compliance. Acta Med Scand Suppl 1984; 683: 35–40
Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–84
Wasson J, Gaudette C, Whaley F, et al. Telephone care as a substitute for routine clinical follow-up. JAMA 1992; 267: 1788–93
Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5
Stanford ’Multifit’ CHF disease management program reduces ER visits by 52% in trial at Kaiser: medication compliance infrastructure is key, Stanford feels. Washington, DC, F-D-C Reports, 1 July 1996: 13-4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Urquhart, J. The Electronic Medication Event Monitor. Clin-Pharmacokinet 32, 345–356 (1997). https://doi.org/10.2165/00003088-199732050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199732050-00001